Breaking Down SG&A Expenses: Merck & Co., Inc. vs MorphoSys AG

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals, understanding the financial health of a company is crucial. This chart provides a fascinating comparison of Selling, General, and Administrative (SG&A) expenses between two industry players: Merck & Co., Inc. and MorphoSys AG, from 2014 to 2023.

Merck & Co., Inc., a giant in the pharmaceutical industry, consistently reported SG&A expenses averaging around $10 billion annually. Notably, 2014 marked their peak at approximately $11.6 billion, while 2020 saw a dip to $8.96 billion, reflecting a 23% decrease. This fluctuation could be attributed to strategic cost management or market conditions.

In contrast, MorphoSys AG, a smaller biotech firm, exhibited a different trend. Their SG&A expenses grew significantly, from $9.69 million in 2014 to nearly $200 million in 2021, a staggering 20-fold increase. This growth underscores their aggressive expansion and investment in administrative capabilities.

This comparison highlights the diverse financial strategies and market positions of these two companies, offering valuable insights for investors and industry analysts.